CIP2A and prostate carcinoma: LRRC59 has been shown to be a binding transporter of the cellular inhibitor PP2A (CIP2A) in prostate cancer,6 and its fusion transcripts are present in various malignancies such as ovarian, esophageal, and prostate cancers.7, 8